We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > pegunigalsidase alfa

News List

Protalix BioTherapeutics, Chiesi Global Announce BLA Acceptance of Pegunigalsidase Alfa americanpharmaceuticalreview
August 14, 2020
Protalix BioTherapeutics together with its development and commercialization partner Chiesi Global Rare Diseases, a unit of Chiesi, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted ...
Protalix BioTherapeutics, Chiesi Complete Enrollment for Trial of Pegunigalsidase Alfa americanpharmaceuticalreview
September 25, 2019
Protalix BioTherapeutics and its development and commercialization partner, Chiesi Farmaceutici announced the completion of enrollment in their Phase III BALANCE clinical study of pegunigalsidase alfa ...